Immunic (IMUX) Cash from Operations (2013 - 2026)

Immunic has disclosed Cash from Operations across 14 years of filings, most recently posting 17301000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 17301000.0, up 20.55% year-over-year; the trailing twelve-month figure through Mar 2026 was 81331000.0 (up 1.5% YoY), and the FY2025 annual result was 85806000.0, down 1.23% from the prior year.
• Cash from Operations came in at 17301000.0 for Q1 2026 at Immunic, up from 19281000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 13596000.0 in Q3 2022 to a low of 24609000.0 in Q2 2025.
• The 5-year median for Cash from Operations is 19513000.0 (2023), against an average of 19049705.88.
• Across the five-year window, Cash from Operations soared 45.65% in 2022 and plunged 63.71% in 2024, its largest moves.
• Immunic's Cash from Operations stood at 15104000.0 in 2022, then increased by 7.13% to 14027000.0 in 2023, then slumped by 63.71% to 22963000.0 in 2024, then grew by 16.03% to 19281000.0 in 2025, then grew by 10.27% to 17301000.0 in 2026.
• The last three Cash from Operations figures came in at 17301000.0 (Q1 2026), 19281000.0 (Q4 2025), and 20140000.0 (Q3 2025), per Business Quant data.